Ehlers-Danlos Syndrome (Classical Type)

None; supportive care only

Ehlers-Danlos syndrome (EDS) encompasses a group of heritable connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Classical EDS (cEDS), the second most common form, is caused primarily by mutations in the COL5A1 gene, which encodes the alpha-1 chain of type V collagen. Type V collagen is a quantitatively minor but functionally critical component of collagen fibrils — it regulates fibril assembly and diameter in skin, tendons, and other tissues.

Classical EDS presents with markedly hyperextensible, velvety skin that bruises easily and heals poorly (forming characteristic atrophic scars), generalized joint hypermobility with frequent dislocations, and chronic pain. Complications can include arterial fragility, though this is more characteristic of the vascular type (vEDS, caused by COL3A1 mutations). There is no specific treatment for cEDS beyond supportive care, physical therapy, and surgical management of complications.

Approximately 90% of classical EDS cases are caused by mutations in COL5A1, with the remaining caused by COL5A2 mutations or rare mutations in COL1A1. COL5A1 mutations include null alleles (causing haploinsufficiency with reduced type V collagen production) and structural mutations (causing dominant-negative effects where mutant collagen disrupts fibril assembly).

The ASO strategy depends on the mutation type. For dominant-negative mutations that produce a structurally abnormal collagen chain, allele-selective gene silencing can target the mutant COL5A1 mRNA for selective degradation while preserving the normal allele. Reducing the dominant-negative protein would improve the quality of collagen fibrils assembled from the remaining normal chains. For splice site mutations that cause aberrant mRNA processing, splice-modulating ASOs can redirect splicing to produce functional or less harmful transcripts.

Connective tissue disorders like EDS present a delivery challenge for ASOs because the target cells (fibroblasts and other connective tissue cells) are distributed throughout the body. However, systemic delivery via subcutaneous injection has been demonstrated to achieve therapeutic ASO concentrations in skin and connective tissue in preclinical models, suggesting that a systemic ASO approach could be feasible.

Pequliar designs personalized ASO candidates for classical Ehlers-Danlos syndrome based on the patient’s specific COL5A1 mutation. The platform determines whether allele-selective silencing, splice modulation, or another strategy is most appropriate, identifies optimal target sites, and provides synthesis-ready sequences with full chemistry assignment and off-target screening.

Design an ASO for Ehlers-Danlos Syndrome (Classical Type)

Describe your mutation and get ranked, synthesis-ready ASO candidates in minutes. $399 per design.

Pequliar is a computational research tool for informational purposes only. All sequences are computationally predicted candidates that have not been experimentally validated. Pequliar does not prescribe, recommend, or administer any compound. Independent validation by qualified professionals is required.